The relevance of this cytokine in autoimmune diseases led to the generation and approval of several TNF-α antagonists such as infliximab, adalimumab and etanercept.92 Infliximab is also included in the guidelines for the treatment of several autoimmune-like syndromes that are associated with immune checkpoint inhibitor treatment that are refractory to corticosteroid treatment.11 This evidence concerns the gene TNF and autoimmune disease.